28471941|t|Basic science and pathogenesis of ageing with HIV: potential mechanisms and biomarkers
28471941|a|: The increased prevalence of age -related comorbidities and mortality is worrisome in ageing HIV-infected patients. Here, we aim to analyse the different ageing mechanisms with regard to HIV infection. Ageing results from the time - dependent accumulation of random cellular damage. Epigenetic modifications and mitochondrial DNA haplogroups modulate ageing. In antiretroviral treatment -controlled patients, epigenetic clock appears to be advanced, and some haplogroups are associated with HIV infection severity. Telomere shortening is enhanced in HIV-infected patients because of HIV and some nucleoside analogue reverse transcriptase inhibitors. Mitochondria -related oxidative stress and mitochondrial DNA mutations are increased during ageing and also by some nucleoside analogue reverse transcriptase inhibitors. Overall, increased inflammation or ' inflammageing ' is a major driver of ageing and could result from cell senescence with secreted proinflammatory mediators, altered gut microbiota, and coinfections. In HIV-infected patients, the level of inflammation and innate immunity activation is enhanced and related to most comorbidities and to mortality. This status could result, in addition to age, from the virus itself or viral protein released from reservoirs, from HIV -enhanced gut permeability and dysbiosis, from antiretroviral treatment, from frequent cytomegalovirus and hepatitis C virus coinfections, and also from personal and environmental factors, as central fat accumulation or smoking. Adaptive immune activation and immunosenescence are associated with comorbidities and mortality in the general population but are less predictive in HIV-infected patients. Biomarkers to evaluate ageing in HIV-infected patients are required. Numerous systemic or cellular inflammatory, immune activation, oxidative stress, or senescence markers can be tested in serum or peripheral blood mononuclear cells. The novel European Study to Establish Biomarkers of Human Ageing MARK-AGE algorithm, evaluating the biological age, is currently assessed in HIV-infected patients and reveals an advanced biological age. Some enhanced inflammatory or innate immune activation markers are interesting but still not validated for the patient's follow-up. To be able to assess patients ' biological age is an important objective to improve their healthspan.
28471941	0	13	Basic science	T062	C0681833
28471941	18	30	pathogenesis	T046	C0699748
28471941	34	40	ageing	T040	C0001811
28471941	46	49	HIV	T047	C0019693
28471941	61	71	mechanisms	T169	C0441712
28471941	76	86	biomarkers	T201	C0005516
28471941	103	113	prevalence	T081	C0220900
28471941	117	120	age	T032	C0001779
28471941	130	143	comorbidities	T078	C0009488
28471941	148	157	mortality	T081	C0178686
28471941	161	170	worrisome	T033	C0233481
28471941	174	180	ageing	T040	C0001811
28471941	181	193	HIV-infected	T047	C0019693
28471941	194	202	patients	T101	C0030705
28471941	213	216	aim	T078	C1947946
28471941	220	227	analyse	T062	C0936012
28471941	242	248	ageing	T040	C0001811
28471941	249	259	mechanisms	T169	C0441712
28471941	275	288	HIV infection	T047	C0019693
28471941	290	296	Ageing	T040	C0001811
28471941	314	318	time	T079	C0040223
28471941	321	330	dependent	T169	C3244310
28471941	331	343	accumulation	T033	C4055506
28471941	354	369	cellular damage	T049	C0599732
28471941	371	395	Epigenetic modifications	T045	C1516924
28471941	400	417	mitochondrial DNA	T114,T123	C0012929
28471941	418	429	haplogroups	T032	C0018591
28471941	430	438	modulate	T082	C0443264
28471941	439	445	ageing	T040	C0001811
28471941	450	474	antiretroviral treatment	T061	C1963724
28471941	487	495	patients	T101	C0030705
28471941	497	513	epigenetic clock	T040	C0085759
28471941	547	558	haplogroups	T032	C0018591
28471941	579	592	HIV infection	T047	C0019693
28471941	593	601	severity	T080	C0439793
28471941	603	622	Telomere shortening	T049	C1515263
28471941	638	650	HIV-infected	T047	C0019693
28471941	651	659	patients	T101	C0030705
28471941	671	674	HIV	T005	C0019682
28471941	684	703	nucleoside analogue	T114,T121	C1579410
28471941	704	736	reverse transcriptase inhibitors	T121	C0282519
28471941	738	750	Mitochondria	T026	C0026237
28471941	760	776	oxidative stress	T049	C0242606
28471941	781	798	mitochondrial DNA	T114,T123	C0012929
28471941	799	808	mutations	T045	C0026882
28471941	830	836	ageing	T040	C0001811
28471941	854	873	nucleoside analogue	T114,T121	C1579410
28471941	874	906	reverse transcriptase inhibitors	T121	C0282519
28471941	927	939	inflammation	T046	C0021368
28471941	945	958	inflammageing	T046	C0021368
28471941	982	988	ageing	T040	C0001811
28471941	1011	1026	cell senescence	T043	C0007581
28471941	1041	1066	proinflammatory mediators	T121	C0243042
28471941	1076	1090	gut microbiota	T001	C2985398
28471941	1096	1108	coinfections	T047	C0275524
28471941	1113	1125	HIV-infected	T047	C0019693
28471941	1126	1134	patients	T101	C0030705
28471941	1140	1145	level	T080	C0441889
28471941	1149	1161	inflammation	T046	C0021368
28471941	1166	1181	innate immunity	T032	C0020969
28471941	1182	1192	activation	T052	C1879547
28471941	1225	1238	comorbidities	T078	C0009488
28471941	1246	1255	mortality	T081	C0178686
28471941	1298	1301	age	T032	C0001779
28471941	1312	1317	virus	T005	C0042776
28471941	1328	1341	viral protein	T116,T123	C0042736
28471941	1356	1366	reservoirs	T078	C0012653
28471941	1373	1376	HIV	T005	C0019682
28471941	1387	1390	gut	T023	C0699819
28471941	1391	1403	permeability	T070	C0031164
28471941	1408	1417	dysbiosis	T046	C3658208
28471941	1424	1448	antiretroviral treatment	T061	C1963724
28471941	1464	1479	cytomegalovirus	T005	C0010825
28471941	1484	1501	hepatitis C virus	T005	C0220847
28471941	1502	1514	coinfections	T047	C0275524
28471941	1543	1564	environmental factors	T169	C1516998
28471941	1577	1593	fat accumulation	T033	C0333574
28471941	1597	1604	smoking	T055	C0037369
28471941	1606	1621	Adaptive immune	T039	C0678209
28471941	1622	1632	activation	T052	C1879547
28471941	1637	1653	immunosenescence	T039	C0596761
28471941	1674	1687	comorbidities	T078	C0009488
28471941	1692	1701	mortality	T081	C0178686
28471941	1709	1727	general population	T098	C0683971
28471941	1741	1751	predictive	T080	C0681890
28471941	1755	1767	HIV-infected	T047	C0019693
28471941	1768	1776	patients	T101	C0030705
28471941	1778	1788	Biomarkers	T201	C0005516
28471941	1792	1800	evaluate	T058	C0220825
28471941	1801	1807	ageing	T040	C0001811
28471941	1811	1823	HIV-infected	T047	C0019693
28471941	1824	1832	patients	T101	C0030705
28471941	1856	1864	systemic	T169	C0205373
28471941	1868	1889	cellular inflammatory	T025	C0440752
28471941	1891	1897	immune	T169	C0439662
28471941	1898	1908	activation	T052	C1879547
28471941	1910	1926	oxidative stress	T049	C0242606
28471941	1942	1949	markers	T201	C0005516
28471941	1957	1963	tested	T169	C0039593
28471941	1967	1972	serum	T031	C0229671
28471941	1976	2010	peripheral blood mononuclear cells	T025	C1321301
28471941	2022	2030	European	T083	C0015176
28471941	2031	2036	Study	T062	C2603343
28471941	2050	2060	Biomarkers	T201	C0005516
28471941	2064	2095	Human Ageing MARK-AGE algorithm	T170	C0002045
28471941	2097	2107	evaluating	T058	C0220825
28471941	2112	2122	biological	T080	C0205460
28471941	2123	2126	age	T032	C0001779
28471941	2153	2165	HIV-infected	T047	C0019693
28471941	2166	2174	patients	T101	C0030705
28471941	2199	2209	biological	T080	C0205460
28471941	2210	2213	age	T032	C0001779
28471941	2229	2241	inflammatory	T169	C0333348
28471941	2245	2258	innate immune	T032	C0020969
28471941	2259	2269	activation	T052	C1879547
28471941	2270	2277	markers	T201	C0005516
28471941	2326	2335	patient's	T101	C0030705
28471941	2336	2345	follow-up	T058	C1522577
28471941	2368	2376	patients	T101	C0030705
28471941	2379	2389	biological	T080	C0205460
28471941	2390	2393	age	T032	C0001779
28471941	2437	2447	healthspan	T078	C0018684